Details

Introduction<br /> GENERAL ASPECTS<br /> Target Family-directed Masterkeys<br /> Drug Discovery from Side Effects<br /> Chemical Genetics in Drug Discovery<br /> Structural Aspects of Binding Site Similarity<br /> TARGET FAMILIES<br /> Knowledge-based Discovery of Biological Targets<br /> Chemical Kinomics<br /> Kinase Inhibitors<br /> Ion Channel Modulators<br /> Phosphodiesterase Inhibitors<br /> Proteochemometrics<br /> CHEMICAL LIBRARIES<br /> Compound Library and Template Design for GPCRs<br /> Computational Filters in Lead Generation<br /> Ligand-based Design of Focused Libraries<br /> Natural Product-derived Combinatorial Libraries<br /> Combinatorial Chemistry in the Chemical Genomics Age<br />

"In summary, this book provides up-to-date insights into the world of chemogenomics. Most chapters are of excellent quality, providing numerous and diverse contributions from industrial practice. "Chemogenomics in Drug Discovery" offers a practical definition of chemogenomics in order to foster a clear understanding of this genome-wide drug-discovery approach. The book is valuable for graduate students anf for academic and industrial researchers who want to learn about modern drug-discovery approaches."<br /> CHEMBIOCHEM - A European Journal of Chemical Biology<br /> <br /> <br /> "The contributions in >Chemogenomics in Drug Discovery< are of very high quality and are clearly presented ... All chapters have a high scientific value, and collectively they contribute a great deal to the understanding of how chemogenomics and scaled-up medicinal chemistry can support the early stages of drug discovery. Therefore, this work is highly relevant for everyone with an intereste in modern drug development, and especially for readers in the pharmaceutical industry."<br /> Ulf Börjesson, Institute of Pharmaceutical Chemistry, University of Marburg, Angewandte Chemie, IE, 3rd May Issue 2005-44/19+ Angewandte Chemie, 3. Maiheft 2005-117/19<br /> <br /> <br /> "... readers hoping to learn about specific aspects will be rewarded with superb writing, good discussions, and excellent examples from current literature."<br /> Steven M. Firestine, Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Journal of Medicinal Chemistry, <br /> Vol. 48, No. 11/2005<br /> <br /> <br /> "This hallmark text marks a breakthrough in the field...vital to the researcher."<br /> Electric Review, April/May 2005<br /> <br /> <br />

Hugo Kubinyi studied chemistry in Vienna, Austria. After his Ph.D. thesis at the Max Planck Institute of Biochemistry in Munich he continued as a PostDoc at the German Cancer Research Centre in Heidelberg. In 1966 he joined Knoll AG, later a subsidiary of BASF AG, and in 1985 he moved to BASF AG. Since 1987, until his retirement in summer 2001, he was responsible for the Molecular Modelling, Protein Crystallography and Drug Design group of BASF, since early 1998 also for Combinatorial Chemistry in the Life Sciences. <br /> He is Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society, and IUPAC Fellow. From his scientific work resulted five books on QSAR, 3D QSAR, and Drug <br /> Design (the German book "Wirkstoffdesign" received the 1999 Book Award of the FCI, Association of Chemical Industry) and about 90 publications. <br /> He is a member of several Scientific Advisory Boards, coeditor of the Wiley-VCH book series "Methods and Principles in Medicinal Chemistry", and member of the Editorial Boards of several scientific journals.<br /> <br /> Gerhard Müller graduated in Organic Chemistry from the University of Frankfurt/Main (Germany) and received his PhD in 1992 at the Technical University of Munich. After two years in the Medicinal Chemistry department of Glaxo Verona (Italy), he joined the central research facility of the Bayer AG, Leverkusen. From 1998 onwards he was project manager of a target family approach in medicinal chemistry. From 2001 to 2003 he headed the chemistry section of Organon's Lead Discovery Unit in Oss (The Netherlands). Since summer 2003, Gerhard Müller is the chief scientific officer of the Munich-based biotech company Axxima Pharmaceuticals AG.<br />

Chemogenomics brings together the most powerful concepts in modern chemistry and biology, linking combinatorial chemistry with genomics and proteomics.<br /> This first reference devoted to the topic covers all stages of the early drug discovery process, from target selection to compound library and lead design. <br /> <br /> From the Contents:<br /> <br /> * Masterkeys and Privileged Structures<br /> * Drug Discovery from Side Effects<br /> * Chemical Genetics in Drug Discovery<br /> * Knowledge-based Discovery of Biological Targets<br /> * Chemical Kinomics<br /> * Compound Library and Template Design<br /> * Computational Filters in Lead Generation<br /> * Ligand-based Design of Focused Libraries<br /> * Natural Product-derived Combinatorial Libraries<br /> <br /> With the combined expertise of 15 research groups from academia and leading pharmaceutical companies, this reference is indispensable reading for every drug developer and medicinal chemist who wants to stay ahead in the search for new and improved drugs.<br />

"... this book provides up-to-date insights into the world of chemogenomics. Most chapters are of excellent quality, providing numerous and diverse contributions from industrial practice. <i>Chemogenomics in Drug Discovery</i> offers a practical definition of chemogenomics in order to foster a clear understanding of this genome-wide drug-discovery approach."<br /> --Thomas Klabunde, Sanofi-Aventis, Frankfurt, <i>ChemBioChem</i>, 4/2005<br /> <br /> "The contributions in <i>Chemogenomics in Drug Discovery</i> are of very high quality and are clearly presented.... All chapters have a high scientific value, and collectively they contribute a great deal to the understanding of how chemogenomics and scaled-up medicinal chemistry can support the early stages of drug discovery. Therefore, this work is highly relevant for everyone with an intereste in modern drug development, and especially for readers in the pharmaceutical industry."<br /> --Ulf Börjesson, Institute of Pharmaceutical Chemistry, University of Marburg, <i>Angewandte Chemie</i>, IE, 3rd May Issue 2005-44/19+ <i>Angewandte Chemie</i>, 3. Maiheft 2005-117/19<br /> <br /> "... readers hoping to learn about specific aspects will be rewarded with superb writing, good discussions, and excellent examples from current literature."<br /> --Steven M. Firestine, Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, <i>Journal of Medicinal Chemistry</i>, Vol. 48, No. 11/2005

DE